Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly To Launch Diabetes Drug Byetta In China

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly has received imported drug approval from China's State FDA for its diabetes drug Byetta (exenatide injection), which is expected to be officially launched in China in the second half of this year. Local experts said the drug provides a new option to diabetes patients who cannot achieve good glycemic control with oral anti-diabetic drugs but are averse to insulin injection. Fixed doses of Byetta are easily injected twice daily with a pen device, dispensing with the current inconvenient method of insulin dosage adjustment according to blood sugar levels. Besides controlling blood sugar, the drug also helps patients lose weight; weight gain is a problem plaguing most diabetics. (Click here for more - Chinese Language)
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072100

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel